- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.03. | TD Cowen reiterates buy on Apogee Therapeutics stock | 2 | Investing.com | ||
| 05.03. | Apogee Therapeutics: Steigende Verluste trotz wachsender Marktchancen | 3 | IT BOLTWISE | ||
| 03.03. | Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial | 1 | Benzinga.com | ||
| 03.03. | Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy | 4 | Investing.com | ||
| APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Apogee Therapeutics reports FY results | 3 | Seeking Alpha | ||
| 03.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | 182 | GlobeNewswire (Europe) | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| 03.03. | Apogee Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 03.03. | Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) | 104 | GlobeNewswire (Europe) | Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head... ► Artikel lesen | |
| 03.03. | Apogee Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 03.02. | Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis | 172 | GlobeNewswire (Europe) | Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.... ► Artikel lesen | |
| 03.02. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.01. | Here's Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 | 2 | Insider Monkey | ||
| 10.12.24 | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | 189 | GlobeNewswire (Europe) | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| 10.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day | 6 | GlobeNewswire (USA) | ||
| 02.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.11.24 | Apogee Therapeutics Announces Agenda for Virtual R&D Day | 2 | GlobeNewswire (USA) | ||
| 18.11.24 | Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Das Unternehmen APOGEE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,15 % bei einem Aktienkurs von 33,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APOGEE THERAPEUTICS INC finden Sie auf Wallstreet Online.
